TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01495247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.~BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.~BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts.
Study: NCT01246323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with Fentanyl+ Morphine
Description: Fentanyl 15 microgram Morphine 0.1-0.5 mg
Study: NCT01650376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
Study: NCT00967018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study: NCT01650376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
Study: NCT02779296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-Octyl Cyanoacrylate Glue
Description: topical
Study: NCT03393572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate.
Description: Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalbuphine
Description: Patients will receive intraperitoneal 5 mg nalbuphine
Study: NCT02596087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem List Suggestion
Description: Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
Study: NCT02184156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL injection of Ampion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL injection of Placebo
Study: NCT00874133

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatment for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motilium
Description: 20 mg motilium thrice daily
Study: NCT04552093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Administration of intra-arterial floxuridine via the HAIP (HAIP chemotherapy) to the liver with concomitant Dutch standard of care systemic FOLFOX (5-FU, leucovorin and oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricumed IP2000V infusion pump
Description: Surgical implantation of hepatic artery infusion pump (HAIP) followed by administration of the combined chemotherapy (HAIP and systemic).
Study: NCT02719795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local injection of local anesthetic into the fascial spaces

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
Study: NCT00925782

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection
Description: Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
Study: NCT01867164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynoclin V
Description: One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vagitrol V
Description: One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
Study: NCT00440518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
Study: NCT01177020

Intervention type: OTHER
Intervention: Biological specimen
Description: Biological specimen taken from placenta
Study: NCT05640531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 771 IV Infusion
Description: subjects will receive intravenous infusion of WCK 771

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Infusion
Description: subjects will receive matching placebo intravenous infusion
Study: NCT04476160

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: children recipe 3 grams by day of cinnamon
Study: NCT00925782

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection
Description: Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.

Intervention type: DRUG
Group type: OTHER
Intervention: Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
Description: Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.

Intervention type: DRUG
Group type: OTHER
Intervention: Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
Description: Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
Study: NCT02298205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma controller medication (Beclomethasone) adjustment strategy
Description: The participant will adjust the dose of Beclomethasone based on symptoms

Intervention type: OTHER
Group type: OTHER
Intervention: Provider-based adjustment
Description: The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
Study: NCT01652820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day
Study: NCT03237754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS device from neuroConn
Description: weak electrical direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS device from neuroConn
Description: weak electrical direct current stimulation
Study: NCT03003468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 200mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
Study: NCT03436927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Balance exercises
Description: Nintendo Wii Fit' training protocol consisted of 'Penguin Slide', 'Table Tilt', 'Ski Slalom', 'Heading' and 'Balance Bubble' games that selected from the Wii Fit Plus balance games section

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Trainer Balance Exercises
Description: Balance Trainer' training protocol consisted of 'Collect Apples', 'Outline', 'Paddle War' and 'Evaluation of Movement' games which were included in the device software and allowed the patients to done balance exercises in different directions.
Study: NCT03752827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipose Derived Regenerative Cells
Description: Adipose-derived regenerative cells isolated with the Transpose Ultra system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid injection into subacrominal space
Study: NCT02957643

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron
Description: oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: oral treatment
Study: NCT04079959

Intervention type: PROCEDURE
Intervention: endometrial biopsy
Description: . Endometrial samples are obtained using a biopsy catheter as follows: the Pipette is inserted through the cervical os and advanced gently until resistance is felt. The inner piton of the device is then withdrawn to create suction, and the endometrial sample is obtained by moving the pipette up and down approximately 2-3 cm within the uterine cavity. The device is rotated 360° to ensure adequate coverage of the area.
Study: NCT02520466

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavanol-rich drink vs flavanol-free drink
Description: Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: flavanol-rich drink vs flavanol-free drink
Description: Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
Study: NCT05788380

Intervention type: OTHER
Group type: OTHER
Intervention: EXERCİSE
Description: EXERCISE FOR HEALTH AND PAIN IMPROVEMENT

Intervention type: OTHER
Group type: OTHER
Intervention: EXERCİSE
Description: EXERCISE FOR HEALTH AND PAIN IMPROVEMENT
Study: NCT04682613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Prevention Program young In Favor of Myself, active teachers
Description: Prevention program: young In Favor of Myself, with teacher participation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Prevention Program young In Favor of Myself, no teacher involvement
Description: Prevention program: young In Favor of Myself, without teacher participation
Study: NCT04351815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short term prehabilitation (2 weeks)
Description: * Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patient will be asked to follow a 2 weeks prehabilitation program~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)
Study: NCT01652820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d
Study: NCT04351815

Intervention type: OTHER
Group type: OTHER
Intervention: No specific intervention
Description: * Standard care: Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patients will be asked to maintain regular physical activity without support~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)
Study: NCT04298853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PRN
Description: Dose given every 3 hours as-needed for severe NAS, defined by a threshold Finnegan score.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine scheduled
Description: Dose given every 3 hours on a scheduled basis and slowly weaned once stabilized.
Study: NCT01652820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d
Study: NCT04201353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer
Description: The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (\~$10) for up to 6 months conditional on visit attendance.
Study: NCT03037671

Intervention type: DEVICE
Intervention: Continuous Glucose Monitor (CGM)
Description: Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
Study: NCT00834795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg tablets
Description: 1 x 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COREG® 25 mg tablets
Description: 1 x 25 mg
Study: NCT02189096

Intervention type: OTHER
Intervention: NEWS and Sepsis Screening
Description: Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.

Intervention type: OTHER
Intervention: Point of care lactate measurement
Description: Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
Study: NCT05363059

Intervention type: DRUG
Intervention: Hypoglycemic drugs
Description: drug

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: surgery
Study: NCT04137575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ConquerFear-Group
Description: The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation Training
Description: The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
Study: NCT01798719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Mediterranean Diet
Description: A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Advice
Description: Only general advice about diet
Study: NCT02877433

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Roxolid short implant, 4 mm length (4)
Description: Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roxolid short implant, 4 mm length (2)
Description: Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
Study: NCT01718704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viberect device
Description: Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
Study: NCT05365932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra auricular device (IAD)
Description: The Intra Auricular Device (IADs) are a pair of inconspicuous, custom fit auricular prosthetic devices.The ear inserts are manufactured using computer-aided design/computer-aided manufacturing (CAD/CAM) technology and are made from a liquid, photo-reactive acrylate (EShell 300), used in hearing aid shells and otoplastics for the last 10 years. They are designed to be placed into the outer third of the ear canals, and they have a small retraction post used to facilitate removal . A red or blue dot, respectively, indicates the right and the left side. The device do not interfere with hearing or speech
Study: NCT01929863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be supplied as oral solution, and will be administered BID \[45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be supplied as oral solution, and will be administered BID \[45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
Study: NCT04890418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketalar, 5 mg/mL Injectable Solution
Description: The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive 10 mL of 0.9% saline. This injection is also performed after the realization of PNB but before tourniquet set up and before start of surgery.
Study: NCT00568672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 5 mg / day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 5 mg / day for 6 months
Study: NCT03810703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg oral capsule
Description: d-amphetamine 10 mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg oral capsule
Description: d-amphetamine 20 mg oral capsule
Study: NCT01202734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl
Description: Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1